Time-dependent decrease in antibody titer and booster vaccine response
mature T/NK-cell neoplasms, HC
The median antibody titers in 11 patients and 26 healthy individuals who had all 3-month, 6-month, and 9-month paired samples and who also received the third dose were compared using the Wilcoxon signed-rank test. Since patients who received third dose before the 6-month blood sampling were excluded, all third doses were administered between 6-month and 9-month blood samplings in this analysis. In HC, the median antibody titer at 6 months was significantly lower than that at 3 months (582.5 (263.3–1067.0) U/ml vs. 913.5 (514.3–1456.3) U/ml, Anti-SARS-CoV-2 S antibody titers after the initial vaccination and booster vaccination in healthy controls and patients with mature T/NK-cell neoplasms. Individuals who did not receive a third dose were excluded from this analysis. The Wilcoxon signed-rank test was used to compare medians of antibody titers in paired individuals. The two short lines show interquartile range (IQR) and the center long line shows the median. HC, healthy controls. M, months